Page 5 - நோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Mass General Brigham unlikely to recommend Alzheimer’s drug to patients on blood thinners Jonathan Saltzman © Provided by The Boston Globe More than a third of patients who took Aduhelm in clinical trials had small brain bleeds or an accumulation of fluid detected by MRI. Mass General Brigham is unlikely to offer Biogen’s controversial new Alzheimer’s drug to patients taking blood thinners because of concerns about the risk of bleeding in the brain, according to two doctors helping to develop a policy on the medicine for the state’s largest health care provider. Dr. Teresa Gomez-Isla and Dr. Kirk Daffner, Alzheimer’s specialists at Massachusetts General Hospital and Brigham and Women’s Hospital, respectively, noted that patients on anticoagulant medications were excluded from clinical trials of the recently approved Aduhelm. The Cambridge biotech’s medicine was associated with “microhemorrhages,” or small amounts of bleeding, in the brains o

University of southern californiaUnited statesNew yorkUnited kingdomLon schneiderJanet woodcockTeresa gomez islaSam gandyKirk daffnerAllison parksHuman servicesDrug administrationHospital departmentOffice of the inspector generalHuman serviceDepartment of health